COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS A SECOND-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN THE UNITED STATES

被引：0
|
作者：
Chen, N. C. [1 ]
McQueen, R. [1 ]
机构：
[1] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE369
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
    Li, Andong
    Wu, Meiyu
    Xie, Ouyang
    Xiang, Heng
    Meng, Kehui
    Tan, Chongqing
    Wang, Long
    Wan, Xiaomin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] COST-EFFECTIVENESS OF SECOND-LINE TREATMENT FOR ADVANCED ENDOMETRIAL CARCINOMA IN TAIWAN: LENVATINIB PLUS PEMBROLIZUMAB VERSUS DOXORUBICIN
    Chiang, S. T.
    Chueh, C. H.
    Ho, P. K.
    Wen, Y. W.
    Shiu, M. N.
    Liu, J. H.
    Li, W. H.
    Tsai, Y. W.
    VALUE IN HEALTH, 2023, 26 (12) : S63 - S63
  • [23] Cost-Effectiveness of Capivasertib as a Second-Line Therapy for Advanced Breast Cancer
    Nguyen, Trang T. H.
    Mital, Shweta
    PHARMACOECONOMICS, 2025, 43 (03) : 351 - 361
  • [24] Cost-effectiveness of pembrolizumab as first-line treatment of locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-based therapy in the United States.
    Lai, Yizhen
    Zhong, Yichen
    Li, Haojie
    Patterson, Karl
    Hale, Oliver
    Meng, Yang
    Frenkl, Tara L.
    Godwin, James Luke
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [25] Efficacy of pembrolizumab as second line therapy for advanced urothelial carcinoma
    Nouhaud, F. -X.
    PROGRES EN UROLOGIE, 2017, 27 (02): : F38 - F39
  • [26] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA
    Xiao, D.
    Zhu, S.
    Sun, W.
    Xuan, J.
    VALUE IN HEALTH, 2019, 22 : S187 - S188
  • [27] Urothelial Carcinoma: Second-Line Therapy with Pembrolizumab prolongs Survival Time
    Dobler, Gabriele
    Aziz, Atiqullah
    AKTUELLE UROLOGIE, 2019, 50 (01) : 14 - 15
  • [28] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [29] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [30] Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis
    Kun Liu
    Youwen Zhu
    Yangying Zhou
    Hong Zhu
    Advances in Therapy, 2023, 40 (4) : 1838 - 1849
12345